https://doi.org/10.4081/vl.2026.14912
When sclerotherapy leaves its mark: prevention and management of cutaneous complications
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 7 April 2026
Sclerotherapy represents a cornerstone in the treatment of chronic venous disease and superficial venous disorders, combining effectiveness, versatility, and a favorable safety profile. Despite these advantages, cutaneous complications remain clinically relevant because of their potential impact on aesthetic outcomes, patient satisfaction, and, in rare cases, tissue integrity. Cutaneous adverse events range from common and usually self-limiting manifestations, such as ecchymosis, hyperpigmentation, and telangiectatic matting, to uncommon but potentially severe complications including skin ulceration and necrosis. This narrative review provides a clinically oriented and critical overview of cutaneous complications associated with sclerotherapy, focusing on pathophysiological mechanisms, patient- and procedure-related risk factors, prevention strategies, and management options. Particular emphasis is placed on practical clinical decision-making, patient counseling, and early recognition of warning signs, with the aim of supporting safe practice and identifying areas in order to support future research.
Downloads
1. Rabe E, Pannier F. Sclerotherapy in the treatment of varicose veins. Dtsch Arztebl Int 2020;117:303-10.
2. De Maeseneer MG, Kakkos SK, Aherne T. Editor's Choice - European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. Eur J Vasc Endovasc Surg 2022;63:184-267. DOI: https://doi.org/10.1016/j.ejvs.2022.06.022
3. Wong M, Parsi K, Myers K, Sclerotherapy of lower limb veins: Indications, contraindications and treatment strategies to prevent complications - A consensus document of the International Union of Phlebology-2023. Phlebology 2023;38:205-58. DOI: https://doi.org/10.1177/02683555231151350
4. Bossart S, Ramelet AA, Seyed Jafari SM. Revealing the origin of postsclerotherapy hyperpigmentation: identification of melanin and hemosiderin as causative pigments in a histopathological study. Phlebology 2026;:217-23. DOI: https://doi.org/10.1177/02683555251357095
5. Gloviczki P, Lawrence PF, Wasan SM. The 2023 Society for Vascular Surgery, American Venous Forum, and American Vein and Lymphatic Society clinical practice guidelines for the management of varicose veins of the lower extremities. Part II: Endorsed by the Society of Interventional Radiology and the Society for Vascular Medicine. J Vasc Surg Venous Lymphat Disord 2024;101670. DOI: https://doi.org/10.1016/j.jvsv.2023.08.011
6. Kang M, Yang A, Lee BB. Skin necrosis following sclerotherapy. Part 1: Differential diagnosis and classification. Phlebology 2022;37:683-92. DOI: https://doi.org/10.1177/02683555221088101
7. Kang M, Yang A, Lee BB. Skin necrosis following sclerotherapy. Part 2: Risk minimisation and management strategies. Phlebology 2022;37:693-701. DOI: https://doi.org/10.1177/02683555221125596
8. Rabe E, Pannier F. Indications, contraindications and performance: European Guidelines for Sclerotherapy in Chronic Venous Disorders. Phlebology 2014;29:26-33. DOI: https://doi.org/10.1177/0268355514528127
9. Rai KM, Rao KS, Maudar KK. Accidental intra-arterial drug injection. Med J Armed Forces India 2017;53:137-9. DOI: https://doi.org/10.1016/S0377-1237(17)30686-X
10. Parsi K, De Maeseneer M, van Rij M, et al. Guidelines for management of actual or suspected inadvertent intra-arterial injection of sclerosants. Phlebology 2024;39:683-719. DOI: https://doi.org/10.1177/02683555241260926
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
